Dermatology · Philadelphia, PA
NPI
1578046603
Since 2018
Specialty
Dermatology
Code 207N00000X
Group practices
1
Medicare group memberships
Hospitals
1
Hospital affiliations
833 Chestnut St
Philadelphia, PA, 19107
Phone (484) 951-4055
Groups this clinician bills Medicare through
Medicare paid, 2024
$179K
4,440 services
Medicare patients, 2024
813
Average age 73
Drug cost, 2024
$534K
1,552 prescriptions
Company payments, 2025
$8,716
From 21 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Jessica B Dijulio was code 17003 (destruction skin lesion), 1,436 times for 247 patients. In total Jessica B Dijulio billed 4,440 services in 30 codes, and Medicare paid $179K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2020-07-14.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 17003 Destruction Skin Lesion | Office | 1,436 | 247 | $4.05 | $5,816 |
| 99214 Office E&M - Established | Office | 1,147 | 709 | $70.91 | $81K |
| 17000 Destruction Skin Lesion | Office | 442 | 331 | $30.06 | $13K |
| 11102 Skin Biopsy | Office | 377 | 313 | $53.76 | $20K |
| 11103 Skin Biopsy | Office | 280 | 156 | $30.34 | $8,495 |
| 17110 Destruction Skin Lesion | Office | 262 | 221 | $62.66 | $16K |
| 99204 Office E&M - New | Office | 177 | 177 | $88.77 | $16K |
| 17004 Destruction Skin Lesion | Office | 72 | 57 | $98.22 | $7,072 |
| 99213 Office E&M - Established | Office | 45 | 37 | $50.73 | $2,283 |
| J3301 Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 40 | 20 | $0.51 | $20.23 |
| 17111 Destruction Skin Lesion | Office | 22 | 21 | $72.68 | $1,599 |
| 69100 Other Organ Systems | Office | 20 | 19 | $40.27 | $805 |
| 11900 Skin | Office | 12 | 11 | $19.58 | $235 |
By year: 2022 $141K for 3,366 services; 2023 $174K for 4,121 services; 2024 $179K for 4,440 services.
Medicare prescription drug claims, 2024
In 2024, the drug Jessica B Dijulio prescribed most often to Medicare patients was Triamcinolone Acetonide, with 338 prescriptions and refills. In total Jessica B Dijulio wrote 1,552 Medicare prescriptions that cost $534K.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Triamcinolone Acetonide Generic | 338 | 384 | 246 | $4,934 |
| Ketoconazole Generic | 277 | 296 | 114 | $4,226 |
| Doxycycline Hyclate Generic | 142 | 192 | 83 | $2,236 |
| Mupirocin Generic | 90 | 90 | 71 | $835 |
| Fluocinonide Generic | 69 | 70 | 47 | $2,236 |
| Clobetasol Propionate Generic | 65 | 70 | 30 | $5,938 |
| Betamethasone Diprop Augmented Betamethasone/Propylene Glyc | 59 | 71 | 44 | $961 |
| Metronidazole Generic | 41 | 43 | 25 | $1,681 |
| Spironolactone Generic | 40 | 58 | Under 11 | $291 |
| Clindamycin Phosphate Generic | 40 | 40 | 23 | $1,700 |
| Tacrolimus Generic | 38 | 42 | 24 | $3,862 |
| Clotrimazole Generic | 38 | 42 | 25 | $809 |
| Dupixent Pen Dupilumab | 35 | 40 | Under 11 | $145K |
| Valacyclovir Valacyclovir Hcl | 20 | 20 | Under 11 | $103 |
| Imiquimod Generic | 19 | 19 | 11 | $9,074 |
Brand drugs: 151 claims; generic drugs: 1,401 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Jessica B Dijulio $8,716 ($8,716 in general payments such as food, travel and fees) from 21 companies. The largest payer was Janssen Biotech, Inc. with $6,306.
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. JNJ | 24 | $6,306 |
| Abbvie Inc. ABBV | 46 | $557 |
| Organon LLC OGN | 19 | $296 |
| Novartis Pharmaceuticals Corporation NVS | 16 | $231 |
| Botanix SB Inc | 20 | $231 |
| Genzyme Corporation SNY | 6 | $172 |
| Sun Pharmaceutical Industries Inc. SUNPHARMA.NS | 9 | $170 |
| LEO Pharma Inc. | 7 | $147 |
| Galderma Laboratories, L.P. GALD.SW | 6 | $108 |
| Amgen Inc. AMGN | 5 | $93.61 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.